Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression

Orly Vardeny, Anne Catherine Pouleur, Madoka Takeuchi, Evan Appelbaum, Anil Verma, Margaret Prescott, Beverly Smith, Bjorn Dahlof, Scott D. Solomon

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Hypothesis/Introduction: We investigated whether diabetes modified the effectiveness of renin-angiotensin-aldosterone system (RAAS) inhibition on left ventricular hypertrophy (LVH) regression in hypertensive patients in the Aliskiren in Left Ventricular Hypertrophy (ALLAY) trial.Materials and methods: Participants (n=465) with LVH and a BMI > 25 kg/m2 were randomized to aliskiren 300mg, losartan 100mg or both daily for 36 weeks, and LVH regression was assessed by cardiac magnetic resonance imaging. Renin concentration, plasma renin activity and aldosterone were assessed in a subset of patients.Results: Patients with diabetes mellitus (DM) (n=111, 24%) were older (61±9 vs. 58±11 years, p=0.03), had higher BMI (32.2±4.2 vs. 30.7 ± 4 kg/m2, p=0.004), higher systolic blood pressure (148±14 vs. 145±14mmHg, p=0.03) and lower eGFR (79±16 vs. 84±16ml/min, p=0.03) at baseline. Combination therapy with aliskiren plus losartan was associated with greater LVH reduction than losartan alone in patients with DM (p=0.01), but not in patients without DM (p=0.91; unadjusted interaction p=0.06; adjusted p = 0.038). In a subset of 138 participants, plasma aldosterone was reduced to a greater extent in patients with DM (p-interaction = 0.004).Conclusions: Patients with DM and LVH may derive differential benefit with dual RAAS inhibition with a combination of aliskiren and losartan compared with losartan alone with respect to LVH reduction. Whether these findings will result in improved outcomes will be further explored in larger studies.

Original languageEnglish (US)
Pages (from-to)265-272
Number of pages8
JournalJRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Issue number2
StatePublished - Jun 2012

Bibliographical note

Funding Information:
This work was supported by Novartis.


  • Diabetes
  • aldosterone
  • angiotensin receptor blocker
  • direct renin inhibitor
  • left ventricular mass


Dive into the research topics of 'Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression'. Together they form a unique fingerprint.

Cite this